Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial

Ashutosh P. Jadhav, Amin Aghaebrahim, Brian T. Jankowitz, Diogo C. Haussen, Ronald F. Budzik, Alain Bonafe, Parita Bhuva, Dileep R. Yavagal, Ricardo A. Hanel, Ameer E. Hassan, Marc Ribo, Christophe Cognard, Cathy A. Sila, Yanchang Zhang, Wade S. Smith, Jeffrey L. Saver, David S. Liebeskind, Raul G. Nogueira, Tudor G. Jovin

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background and Purpose- It is unknown whether the benefit of thrombectomy in late presenting acute stroke patients with imaging evidence of clinical-infarct mismatch is different in patients presenting with wake-up stroke compared with those presenting with witnessed onset or unwitnessed onset. Methods- Prespecified secondary analysis was performed from DAWN (Diffusion Weighted Imaging [DWI] or Computerized Tomography Perfusion [CTP] Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention), a multicenter, prospective, randomized clinical trial with blinded end point assessment comparing thrombectomy with the Trevo device against standard medical therapy in patients with acute stroke and clinical-infarct mismatch presenting 6 to 24 hour after the time last seen well. For the purposes of this study, the primary outcome was the proportion of modified Rankin Scale score 0 to 2 at 90 days. Univariable analysis and multivariable logistic regression was used to assess the relationship between outcome and mode of onset. Results- All 206 enrolled patients were included in the study. Mode of onset was: wake-up stroke (55.3%, n=114), witnessed onset (12.1%, n=25), and unwitnessed onset (32.5%, n=67) with median time last seen well to randomization (13.4±3.7, 10.0±3.7, 14.1±4.9 hours) respectively. Rates of 90-day modified Rankin Scale score of 0 to 2 and symptomatic intracerebral hemorrhage in the thrombectomy arm were not statistically different across patient onset subtypes (P=0.79 and P=0.40, respectively). The benefit of thrombectomy compared with best medical therapy was maintained across all 3 onset modes (rates of 90-day modified Rankin Scale score of 0 to 2 in patients allocated to thrombectomy versus control: wake-up stroke-49.3% versus 10.6%, witnessed onset-63.6% versus 21.4%, UW-41.4% versus 13.2%; P×interaction=0.79). In univariable and multivariable analyses, mode of onset was not identified as a significant predictor of modified Rankin Scale score 0 to 2 at 90 days. Conclusions- In patients with acute ischemic stroke presenting between 6 and 24 hours from time last seen well and harboring clinical-infarct mismatch, the benefit of thrombectomy was similar regardless of the wake-up, unwitnessed, or witnessed mode of onset.

Original languageEnglish (US)
Pages (from-to)3141-3146
Number of pages6
JournalStroke
Volume50
Issue number11
DOIs
StatePublished - Nov 1 2019
Externally publishedYes

Keywords

  • prognosis
  • reperfusion
  • stroke
  • thrombectomy
  • treatment outcome

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial'. Together they form a unique fingerprint.

  • Cite this

    Jadhav, A. P., Aghaebrahim, A., Jankowitz, B. T., Haussen, D. C., Budzik, R. F., Bonafe, A., Bhuva, P., Yavagal, D. R., Hanel, R. A., Hassan, A. E., Ribo, M., Cognard, C., Sila, C. A., Zhang, Y., Smith, W. S., Saver, J. L., Liebeskind, D. S., Nogueira, R. G., & Jovin, T. G. (2019). Benefit of Endovascular Thrombectomy by Mode of Onset: Secondary Analysis of the DAWN Trial. Stroke, 50(11), 3141-3146. https://doi.org/10.1161/STROKEAHA.119.025795